Fig. 4From: Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variantsThe role of AD biomarkers in the clinical setting. AD, Alzheimer’s disease; CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; NfL, neurofilament light chain; PET, positron emission tomographyBack to article page